---
title: "Ono Pharmaceutical Co., Ltd. (OPHLY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OPHLY.US.md"
symbol: "OPHLY.US"
name: "Ono Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-21T22:30:52.927Z"
locales:
  - [en](https://longbridge.com/en/quote/OPHLY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OPHLY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OPHLY.US.md)
---

# Ono Pharmaceutical Co., Ltd. (OPHLY.US)

## Company Overview

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.ono-pharma.com](https://www.ono-pharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: B (0.35)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 12 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 6.47% |  |
| Net Profit YoY | 40.10% |  |
| P/B Ratio | 1.34 |  |
| Dividend Ratio | 3.29% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7148572671.24 |  |
| Revenue | 3398891357.58 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.54% | B |
| Profit Margin | 13.53% | B |
| Gross Margin | 72.52% | A |
| Revenue YoY | 6.47% | C |
| Net Profit YoY | 40.10% | B |
| Total Assets YoY | -2.48% | D |
| Net Assets YoY | 1.92% | C |
| Cash Flow Margin | 196.11% | B |
| OCF YoY | 6.47% | C |
| Turnover | 0.48 | C |
| Gearing Ratio | 22.58% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ono Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "6.47%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "40.10%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.34",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.29%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7148572671.24",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3398891357.58",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.54%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "13.53%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "72.52%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "6.47%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "40.10%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.48%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.92%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "196.11%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "6.47%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "22.58%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 15.55 | 28/190 | 19.35 | 18.08 | 15.81 |
| PB | 1.34 | 66/190 | 1.33 | 1.11 | 0.98 |
| PS (TTM) | 2.10 | 58/190 | 2.10 | 1.80 | 1.59 |
| Dividend Yield | 3.29% | 10/190 | 4.85% | 3.96% | 3.31% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/OPHLY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/OPHLY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/OPHLY.US/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**